STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLPT
  4. [Form 4] ClearPoint Neuro, Inc. Insider Trading Activity

ClearPoint Neuro (CLPT) CFO vests RSUs, withholds shares for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ClearPoint Neuro, Inc.’s Chief Financial Officer Danilo D’Alessandro reported routine equity compensation activity. He exercised 18,765 restricted stock units, converting them into the same number of common shares at a stated price of $0.00 per share as part of a scheduled vesting.

To cover tax obligations from this vesting, 9,548 common shares were delivered back to ClearPoint Neuro at $10.00 per share, classified as a tax-withholding disposition rather than an open-market sale. After these transactions, D’Alessandro directly holds 84,622 common shares of ClearPoint Neuro.

Positive

  • None.

Negative

  • None.
Insider D'Alessandro Danilo
Role Chief Financial Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 18,765 $0.00 --
Exercise Common Stock 18,765 $0.00 --
Tax Withholding Common Stock 9,548 $10.00 $95K
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 94,170 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
D'Alessandro Danilo
(Last) (First) (Middle)
C/O CLEARPOINT NEURO, INC.
120 S. SIERRA AVE., SUITE 100
(Street)
SOLANA BEACH CA 92075
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/06/2026 M 18,765 A (1) 94,170 D
Common Stock 03/06/2026 F 9,548(2) D $10 84,622 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 03/06/2026 M 18,765 (1) (1) Common Stock 18,765 (1) 0 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.
/s/ Danilo D'Alessandro 03/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for its CFO?

ClearPoint Neuro’s CFO Danilo D’Alessandro reported routine equity compensation activity. He exercised 18,765 restricted stock units into common shares on their scheduled vesting date and had 9,548 of those shares withheld to satisfy related tax obligations.

How many ClearPoint Neuro (CLPT) shares did the CFO acquire through RSU vesting?

The CFO acquired 18,765 shares of ClearPoint Neuro common stock through the settlement of restricted stock units. Each unit converted into one share, reflecting scheduled vesting rather than an open-market purchase, and forming part of his ongoing equity-based compensation.

Why were some ClearPoint Neuro (CLPT) shares delivered back in the Form 4 filing?

Of the vested shares, 9,548 were delivered back to ClearPoint Neuro to cover tax withholding obligations. This is reported with transaction code “F” and represents a tax-withholding disposition, not a discretionary sale into the open market by the executive.

What is the CFO’s ClearPoint Neuro (CLPT) shareholding after these transactions?

Following the RSU vesting and related tax withholding, the CFO directly holds 84,622 shares of ClearPoint Neuro common stock. This figure reflects his post-transaction ownership and helps investors understand the size of his remaining equity stake in the company.

Were the ClearPoint Neuro (CLPT) insider transactions open-market buys or sells?

The reported transactions were not open-market buys or sells. They involved the exercise of 18,765 restricted stock units into shares and a related tax-withholding disposition of 9,548 shares back to the company, typical of scheduled equity compensation events.